Objective:To study the clinical efficacy of rosuvastatin combined with ramipril in the treatment of primary hypertension with coronary heart disease and its effect on serum hs-CRP and MMP9 levels.Methods:120 ca-ses of primary hypertension complicated with coronary heart disease were selected as the subjects.According to the random number table method,60 cases were divided into control group and study group.Patients in the control group were treated with ramipril and the study group received rosuvastatin combined with ramipril.After 2 months of treatment,the changes of blood pressure,serum hs-CRP,MMP9 and angina pectoris were compared before and after treatment.Results:After 2 months of treatment,the diastolic blood pressure and systolic blood pressure of the two groups were lower than those before treatment,and the difference was statistically significant(P<0.05).After treatment,the improvement of angina pectoris in the study group was better than that in the control group,the difference was statistically significant(P<0.05).After 2 months of treatment,the levels of serum hs-CRP and MMP9 in the two groups were lower than those before treatment,and the difference was statistically significant(P<0.05).Conclusion:Patients with primary hypertension complicated with coronary heart disease given rosuvastatin combined with ramipril treatment effect is very significant,which can effectively reduce the blood pressure and ser-um hs-CRP,MMP9 levels,reduce angina pectoris,promote myocardial contraction,diastolic function recovery.%目的:研究瑞舒伐他汀联合雷米普利治疗原发性高血压合并冠心病的临床疗效及对血清hs-CRP、M M P9水平的影响.方法:选取原发性高血压合并冠心病患者120例作为研究对象,根据随机数表法分为对照组、研究组,各60例.对照组患者采用雷米普利治疗,研究组患者采用瑞舒伐他汀联合雷米普利治疗.治疗2个月后,比较两组患者治疗前后血压、血清超敏C-反应蛋白(hs-CRP)、基质金属蛋白酶9(M M P9)水平变化及心绞痛改善效果.结果:治疗2个月后,两组患者舒张压、收缩压水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,研究组患者心绞痛改善效果优于对照组,差异有统计学意义(P<0.05);治疗2个月后,两组患者血清hs-CRP、M M P9水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05).结论:给予原发性高血压合并冠心病患者瑞舒伐他汀联合雷米普利治疗效果显著,能有效降低患者血压及血清hs-CRP、M M P9水平,减少心绞痛发作,促进心肌收缩、舒张功能恢复.
展开▼
